Terms: = Liver cancer AND KDM5C, XE169, SMCX, JARID1C, 8242, ENSG00000126012, DXS1272E, MRXSJ, MRXJ, RP11-258C19_2 AND Treatment
31389 results:
1. Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma.
Leek LVM; Notohardjo JCL; de Joode K; Velker EL; Haanen JBAG; Suijkerbuijk KPM; Aarts MJB; de Groot JWB; Kapiteijn E; van den Berkmortel FWPJ; Westgeest HM; de Gruijl TD; Retel VP; Cuppen E; van der Veldt AAM; Labots M; Voest EE; van de Haar J; van den Eertwegh AJM
Sci Rep; 2024 May; 14(1):11244. PubMed ID: 38755213
[TBL] [Abstract] [Full Text] [Related]
2. Second Chance for Cure: Stereotactic Ablative Radiotherapy in Oligometastatic Disease.
Salim N; Tumanova K; Popodko A; Libson E
JCO Glob Oncol; 2024 May; 10():e2300275. PubMed ID: 38754052
[TBL] [Abstract] [Full Text] [Related]
3. treatment and prognosis study of spontaneous rupture hemorrhage in hepatocellular carcinoma: Recommendations for adding the A1 stage to the BCLC staging system.
Ni Q; Jia H; Zhang Y; Lu J; Chang H
Cancer Med; 2024 May; 13(10):e6952. PubMed ID: 38752672
[TBL] [Abstract] [Full Text] [Related]
4. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
Dang J; Xu G; Guo G; Zhang H; Shang L
J Cancer Res Clin Oncol; 2024 May; 150(5):255. PubMed ID: 38750370
[TBL] [Abstract] [Full Text] [Related]
5. Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience.
Sukrithan V; Armbruster H; Rogers S; Vogt SM; Grenade C; Verschraegen C; Zhou Y; Goyal A; Natwa M; Hussein A; Barr H; Konate D; Batdorf R; Brown A; Williams B; Zhao S; Wei L; Xu M; Shah MH; Konda B
PLoS One; 2024; 19(5):e0298824. PubMed ID: 38748739
[TBL] [Abstract] [Full Text] [Related]
6. Dynamic evaluation of liver fibrosis to assess hepatocellular carcinoma risk in patients with chronic hepatitis B receiving nucleoside analogs treatment.
Luo J; Yuan M; Li S; Chen L; Zhou M; Li H; Bai X; Zhang Z; Zeng W; Sun X; Zhang Q; Chen Y; Zhou L
Rev Inst Med Trop Sao Paulo; 2024; 66():e27. PubMed ID: 38747848
[TBL] [Abstract] [Full Text] [Related]
7. Rice bran arabinoxylan compound as a natural product for cancer treatment - an evidence-based assessment of the effects and mechanisms.
Ooi SL; Micalos PS; Kim J; Pak SC
Pharm Biol; 2024 Dec; 62(1):367-393. PubMed ID: 38745507
[TBL] [Abstract] [Full Text] [Related]
8. [Aprospective study of detection and clinical significance of bone marrow tumor cells in small cell lung cancer].
Wang Y; Lu BH; Gao Y; Liu YX; Hu MM; Che NY; Lin HF; Li HX; Zhang HM; Zhang TM
Zhonghua Zhong Liu Za Zhi; 2024 May; 46(5):419-427. PubMed ID: 38742355
[No Abstract] [Full Text] [Related]
9. Multiple asynchronous recurrence as a predictive factor for refractoriness against locoregional and surgical therapy in patients with intermediate-stage hepatocellular carcinoma.
Kasuga R; Taniki N; Chu PS; Tamura M; Tabuchi T; Yamaguchi A; Hayatsu S; Koizumi J; Ojiro K; Hoshi H; Kaneko F; Morikawa R; Noguchi F; Yamataka K; Usui S; Ebinuma H; Itano O; Hasegawa Y; Abe Y; Kitago M; Inoue M; Nakatsuka S; Jinzaki M; Kitagawa Y; Kanai T; Nakamoto N
Sci Rep; 2024 May; 14(1):10896. PubMed ID: 38740983
[TBL] [Abstract] [Full Text] [Related]
10. Projected estimates of cancer in Canada in 2024.
Brenner DR; Gillis J; Demers AA; Ellison LF; Billette JM; Zhang SX; Liu JL; Woods RR; Finley C; Fitzgerald N; Saint-Jacques N; Shack L; Turner D;
CMAJ; 2024 May; 196(18):E615-E623. PubMed ID: 38740416
[TBL] [Abstract] [Full Text] [Related]
11. Blood Pressure, Readmission, and Mortality Among Patients Hospitalized With Acute Kidney Injury.
Griffin BR; Vaughan-Sarrazin M; Shi Q; Ten Eyck P; Reisinger HS; Kennelty K; Good MK; Swee ML; Yamada M; Lund BC; Jalal DI
JAMA Netw Open; 2024 May; 7(5):e2410824. PubMed ID: 38739389
[TBL] [Abstract] [Full Text] [Related]
12. Seven oral traditional Chinese medicine combined with chemotherapy for the treatment of non-small cell lung cancer: a network meta-analysis.
Liu K; Li Q; Lu X; Fan X; Yang Y; Xie W; Kang J; Sun S; Zhao J
Pharm Biol; 2024 Dec; 62(1):404-422. PubMed ID: 38739082
[TBL] [Abstract] [Full Text] [Related]
13. Distinct autoantibody profiles across checkpoint inhibitor types and toxicities.
Mu-Mosley H; von Itzstein MS; Fattah F; Liu J; Zhu C; Xie Y; Wakeland EK; Park JY; Kahl BS; Diefenbach CS; Gerber DE
Oncoimmunology; 2024; 13(1):2351255. PubMed ID: 38737792
[TBL] [Abstract] [Full Text] [Related]
14. [Curative effect of percutaneous microwave ablation therapy on hepatocellular carcinoma survival: a 15-year real-world study].
Luo YC; Lang ML; Cai WJ; Han ZY; Liu FY; Cheng ZG; Yu XL; Dou JP; Li X; Tan SL; Dong XJ; Liang P; Yu J
Zhonghua Gan Zang Bing Za Zhi; 2024 Apr; 32(4):332-339. PubMed ID: 38733188
[No Abstract] [Full Text] [Related]
15. Receptor Targeting Using Copolymer-Modified Gold Nanoparticles for pCMV-Luc Gene Delivery to liver cancer Cells In Vitro.
Zenze M; Singh M
Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732235
[TBL] [Abstract] [Full Text] [Related]
16. Enrichment and Evaluation of Antitumor Properties of Total Flavonoids from
Yang S; Chu G; Wu J; Zhang G; Du L; Lin R
Molecules; 2024 Apr; 29(9):. PubMed ID: 38731467
[TBL] [Abstract] [Full Text] [Related]
17. Clinical features of patients with carcinoma soft tissue metastases as surgical indications: a retrospective cohort study.
Morinaga S; Yamamoto N; Hayashi K; Takeuchi A; Miwa S; Igarashi K; Taniguchi Y; Asano Y; Nojima T; Tsuchiya H
BMC Cancer; 2024 May; 24(1):577. PubMed ID: 38730358
[TBL] [Abstract] [Full Text] [Related]
18. Phenotyping Hepatic Immune-Related Adverse Events in the Setting of Immune Checkpoint Inhibitor Therapy.
Feldman TC; Kaplan DE; Lin A; La J; Lee JSH; Aljehani M; Tuck DP; Brophy MT; Fillmore NR; Do NV
JCO Clin Cancer Inform; 2024 May; 8():e2300159. PubMed ID: 38728613
[TBL] [Abstract] [Full Text] [Related]
19. Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.
Wang DS; Ren C; Li SS; Fong WP; Wu XJ; Xiao J; Li BK; Zheng Y; Ding PR; Chen G; Qiu MZ; Wang ZQ; Wang FH; Luo HY; Wang F; Wang XZ; Wang LY; Xie DJ; Chen T; Li LR; Lu ZH; Zhai XH; Liu TS; Yuan Y; Chen JQ; Tan Q; Pan ZZ; Wan DS; Zhang R; Yuan YF; Xu RH; Li YH
PLoS Med; 2024 May; 21(5):e1004389. PubMed ID: 38728364
[TBL] [Abstract] [Full Text] [Related]
20. Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study.
Ren S; Xiong A; Yu J; Wang X; Han B; Pan Y; Zhao J; Cheng Y; Hu S; Liu T; Li Y; Cheng Y; Feng J; Yi S; Gu S; Gao S; Luo Y; Liu Y; Liu C; Duan H; Wang S; Yang X; Fan J; Zhou C
Cancer Immunol Immunother; 2024 May; 73(7):124. PubMed ID: 38727837
[TBL] [Abstract] [Full Text] [Related]
[Next]
